{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:36:16Z","timestamp":1786703776218,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Osteoporos"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>\n                      <jats:italic>Summary<\/jats:italic>\n                    <\/jats:title>\n                    <jats:p>Osteoporosis treatment does not normalize BMD. We hypothesized cyclic romosozumab dosing might provide greater BMD increases. Cyclic therapy (six romosozumab monthly doses then one denosumab dose) produced broadly similar BMD increases as previously reported for 12 romosozumab doses. A second cycle further increased spine and hip BMD but with a blunted response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Evaluating novel osteoporosis medication approaches to maximize BMD is reasonable. A bone remodeling-based cyclic approach, i.e., activate, depress, free and repeat (ADFR), has been proposed. We hypothesized that short course romosozumab followed by denosumab represents an appropriate cycle. This exploratory retrospective case series reports six months of romosozumab treatment then one denosumab dose, followed by a second identical cycle.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Women at very high fracture risk were offered cyclic therapy. DXA was obtained at baseline, 1 and 2\u00a0years. Data from 41 women treated for 1, and 18 for 2\u00a0years are reported. Percent BMD change from baseline was evaluated by ANOVA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Patient mean (SD) age and BMI were 68.8 (6.6) years and 25.6 (5.0) kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      respectively. Mean total hip T-score was -2.5, FRAX estimated hip fracture risk was 6.9%. After one cycle, mean\u2009\u00b1\u2009SEM% BMD increase (all p\u2009&lt;\u20090.001) from baseline at the lumbar spine (LS), total hip (TH) and femur neck (FN) was 12.6\u2009\u00b1\u20091.1%, 5.9\u2009\u00b1\u20090.8% and 4.4\u2009\u00b1\u20090.9% respectively. In 18 women completing a second cycle, BMD further increased to\u2009+\u200917.5% and\u2009+\u20098.7% at LS and TH, respectively. In a subset (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200914) CTX was reduced from baseline (mean -78%) before cycle two with 11 below the lower limit of normal.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>At one year, six monthly romosozumab doses then one denosumab dose substantially increased BMD. A second cycle further increased LS and TH BMD, but the response was blunted perhaps reflecting persistent turnover suppression by denosumab. Evaluation of novel romosozumab dosing approaches is indicated.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11657-026-01750-5","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:10:45Z","timestamp":1786702245000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Revisiting the activate depress free and repeat (ADFR) paradigm: Clinical use of cyclic romosozumab"],"prefix":"10.1007","volume":"21","author":[{"given":"Kristyn","family":"Hare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawna","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Morganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Kimmel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Binkley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"key":"1750_CR1","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532\u20131543","journal-title":"N Engl J Med"},{"key":"1750_CR2","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1210\/jc.2018-00163","volume":"103","author":"HG Bone","year":"2018","unstructured":"Bone HG, Cosman F, Miller PD et al (2018) ACTIVExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. J Clin Endocrinol Metab 103:2949\u20132957","journal-title":"J Clin Endocrinol Metab"},{"key":"1750_CR3","doi-asserted-by":"publisher","first-page":"724","DOI":"10.20945\/2359-3997000000564","volume":"66","author":"M Chandran","year":"2022","unstructured":"Chandran M (2022) The why and how of sequential and combination therapy in osteoporosis. A review of the current evidence. Arch Endocrinol Metab 66:724\u2013738","journal-title":"Arch Endocrinol Metab"},{"key":"1750_CR4","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1210\/jc.2013-4440","volume":"99","author":"BZ Leder","year":"2014","unstructured":"Leder BZ, Tsai JN, Uihlein AV, Burnett-Bowie SA, Zhu Y, Foley K, Lee H, Neer RM (2014) Two years of denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metabol 99:1694\u20131700","journal-title":"J Clin Endocrinol Metabol"},{"key":"1750_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/jbmr.238","volume":"26","author":"F Cosman","year":"2011","unstructured":"Cosman F, Eriksen EF, Recknor C et al (2011) Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1\u201334)] in postmenopausal osteoporosis. J Bone Miner Res 26:503\u2013511","journal-title":"J Bone Miner Res"},{"key":"1750_CR6","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/jbmr.3850","volume":"35","author":"F Cosman","year":"2020","unstructured":"Cosman F, McMahon D, Dempster D, Nieves JW (2020) Standard versus cyclic teriparatide and denosumab treatment for osteoporosis: a randomized trial. J Bone Miner Res 35:213\u2013225","journal-title":"J Bone Miner Res"},{"key":"1750_CR7","doi-asserted-by":"publisher","first-page":"2769","DOI":"10.1210\/jc.2015-1715","volume":"100","author":"F Cosman","year":"2015","unstructured":"Cosman F, Nieves JW, Zion M, Garrett P, Neubort S, Dempster D, Lindsay R (2015) Daily or cyclical teriparatide treatment in women with osteoporosis on no prior therapy and women on alendronate. J Clin Endocrinol Metab 100:2769\u20132776","journal-title":"J Clin Endocrinol Metab"},{"key":"1750_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116618","volume":"167","author":"A Ganapathy","year":"2023","unstructured":"Ganapathy A, Nieves JW, Keaveny TM, Cosman F (2023) Effects of four-year cyclic versus two-year daily teriparatide treatment on volumetric bone density and bone strength in postmenopausal women with osteoporosis. Bone 167:116618","journal-title":"Bone"},{"key":"1750_CR9","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11657-021-00933-6","volume":"16","author":"H Goel","year":"2021","unstructured":"Goel H, Libber J, Borchardt G, Krueger D, Binkley N (2021) A pilot study comparing daily teriparatide with monthly cycles of teriparatide and raloxifene. Arch Osteoporos 16:70","journal-title":"Arch Osteoporos"},{"key":"1750_CR10","doi-asserted-by":"crossref","unstructured":"Frost HM (1979) Treatment of osteoporoses by manipulation of coherent bone cell populations. Clin Orthop Relat Res 143:227\u2013244","DOI":"10.1097\/00003086-197909000-00038"},{"key":"1750_CR11","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S0030-5898(20)31376-6","volume":"12","author":"HM Frost","year":"1981","unstructured":"Frost HM (1981) Coherence treatment of osteoporoses. Orthop Clin North Am 12:649\u2013669","journal-title":"Orthop Clin North Am"},{"key":"1750_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/BF02405344","volume":"36","author":"HM Frost","year":"1984","unstructured":"Frost HM (1984) The ADFR concept revisited. Calcif Tissue Int 36:349\u2013353","journal-title":"Calcif Tissue Int"},{"key":"1750_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/8756-3282(91)90038-K","volume":"12","author":"T Steiniche","year":"1991","unstructured":"Steiniche T, Hasling C, Charles P, Eriksen EF, Melsen F, Mosekilde L (1991) The effects of etidronate on trabecular bone remodeling in postmenopausal spinal osteoporosis: a randomized study comparing intermittent treatment and an ADFR regime. Bone 12:155\u2013163","journal-title":"Bone"},{"key":"1750_CR14","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1002\/jbmr.5650040203","volume":"4","author":"LE Mallette","year":"1989","unstructured":"Mallette LE, LeBlanc AD, Pool JL, Mechanick JI (1989) Cyclic therapy of osteoporosis with neutral phosphate and brief, high-dose pulses of etidronate. J Bone Miner Res 4:143\u2013148","journal-title":"J Bone Miner Res"},{"key":"1750_CR15","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/8756-3282(94)90272-0","volume":"15","author":"BY Lin","year":"1994","unstructured":"Lin BY, Jee WS, Ma YF, Ke HZ, Kimmel DB, Li XJ (1994) Effects of prostaglandin E2 and risedronate administration on cancellous bone in older female rats. Bone 15:489\u2013496","journal-title":"Bone"},{"key":"1750_CR16","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/8756-3282(93)90185-D","volume":"14","author":"WS Jee","year":"1993","unstructured":"Jee WS, Tang L, Ke HZ, Setterberg RB, Kimmel DB (1993) Maintaining restored bone with bisphosphonate in the ovariectomized rat skeleton: dynamic histomorphometry of changes in bone mass. Bone 14:493\u2013498","journal-title":"Bone"},{"key":"1750_CR17","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/jbmr.5650070913","volume":"7","author":"LY Tang","year":"1992","unstructured":"Tang LY, Jee WS, Ke HZ, Kimmel DB (1992) Restoring and maintaining bone in osteopenic female rat skeleton: I. Changes in bone mass and structure. J Bone Miner Res 7:1093\u20131104","journal-title":"J Bone Miner Res"},{"key":"1750_CR18","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S8756-3282(98)00146-X","volume":"24","author":"HZ Ke","year":"1999","unstructured":"Ke HZ, Crawford DT, Qi H, Pirie CM, Simmons HA, Chidsey-Frink KL, Chen HK, Jee WS, Thompson DD (1999) Droloxifene does not blunt bone anabolic effects of prostaglandin E2, but maintains prostaglandin E2-restored bone in aged, ovariectomized rats. Bone 24:41\u201347","journal-title":"Bone"},{"key":"1750_CR19","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1359\/jbmr.1997.12.2.267","volume":"12","author":"YF Ma","year":"1997","unstructured":"Ma YF, Lin BY, Jee WS, Lin CH, Chen YY, Ke HZ, Li XJ (1997) Prostaglandin E2 (PGE2) and risedronate was superior to PGE2 alone in maintaining newly added bone in the cortical bone site after withdrawal in older intact rats. J Bone Miner Res 12:267\u2013275","journal-title":"J Bone Miner Res"},{"key":"1750_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","volume":"26","author":"PM Camacho","year":"2020","unstructured":"Camacho PM, Petak SM, Binkley N et al (2020) American association of clinical endocrinologists\/American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract 26:1\u201346","journal-title":"Endocr Pract"},{"key":"1750_CR21","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES (2022) The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 33:2049\u20132102","journal-title":"Osteoporos Int"},{"key":"1750_CR22","doi-asserted-by":"publisher","first-page":"E1333","DOI":"10.1503\/cmaj.221647","volume":"195","author":"SN Morin","year":"2023","unstructured":"Morin SN, Feldman S, Funnell L et al (2023) Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update. Can Med Assoc J 195:E1333-e1348","journal-title":"Can Med Assoc J"},{"key":"1750_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2025.117627","volume":"201","author":"Y Etani","year":"2025","unstructured":"Etani Y, Noguchi T, Yukishima T et al (2025) Impact of baseline PINP on the BMD increase with romosozumab, teriparatide, and denosumab in treatment-na\u00efve primary osteoporosis: a retrospective cohort study. Bone 201:117627","journal-title":"Bone"},{"key":"1750_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-025-01598-1","volume":"20","author":"J Everts-Graber","year":"2025","unstructured":"Everts-Graber J, Ferrari S, Popp A et al (2025) Early transition from short-term romosozumab to antiresorptive therapies: analysis of 26 cases. Arch Osteoporos 20:106","journal-title":"Arch Osteoporos"},{"key":"1750_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/jbmr\/zjae196","volume":"40","author":"T Kobayakawa","year":"2025","unstructured":"Kobayakawa T, Nakamura Y (2025) Verifying the effectiveness of romosozumab re-administration on bone mineral density. J Bone Miner Res 40:201\u2013210","journal-title":"J Bone Miner Res"},{"key":"1750_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-05187-7","volume":"15","author":"Y Sobue","year":"2025","unstructured":"Sobue Y, Kosugiyama H, Asai S et al (2025) A randomized controlled trial comparing romosozumab and denosumab in elderly women with primary osteoporosis and knee osteoarthritis. Sci Rep 15:22441","journal-title":"Sci Rep"},{"key":"1750_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.bone.2017.07.005","volume":"103","author":"H Ishibashi","year":"2017","unstructured":"Ishibashi H, Crittenden DB, Miyauchi A, Libanati C, Maddox J, Fan M, Chen L, Grauer A (2017) Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study. Bone 103:209\u2013215","journal-title":"Bone"},{"key":"1750_CR28","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, Grauer A, Boonen S et al (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412\u2013420","journal-title":"N Engl J Med"},{"key":"1750_CR29","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML, Karaplis AC, Lorentzon M, Thomas T, Maddox J, Fan M, Meisner PD, Grauer A (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"1750_CR30","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1007\/s00198-026-07864-3","volume":"37","author":"DL Kendler","year":"2026","unstructured":"Kendler DL, Habert J, Khan AA et al (2026) Clarifying clinically treatment-naive status for osteoporosis patients. Osteoporos Int 37:857\u2013865","journal-title":"Osteoporos Int"},{"key":"1750_CR31","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.eprac.2024.01.014","volume":"30","author":"F Cosman","year":"2024","unstructured":"Cosman F, Langdahl B, Leder BZ (2024) Treatment sequence for osteoporosis. Endocr Pract 30:490\u2013496","journal-title":"Endocr Pract"},{"key":"1750_CR32","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S2213-8587(25)00319-5","volume":"14","author":"BZ Leder","year":"2026","unstructured":"Leder BZ, Ramchand SK, Jordan M, Ryan S, Patnaik A, Lee H, Tsai JN (2026) 3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled trial. Lancet Diabetes Endocrinol 14:216\u2013222","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1750_CR33","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s001980070097","volume":"11","author":"R Dowd","year":"2000","unstructured":"Dowd R, Recker RR, Heaney RP (2000) Study subjects and ordinary patients. Osteoporos Int 11:533\u2013536","journal-title":"Osteoporos Int"},{"key":"1750_CR34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/jbmr.4457","volume":"37","author":"EF Eriksen","year":"2022","unstructured":"Eriksen EF, Chapurlat R, Boyce RW, Shi Y, Brown JP, Horlait S, Betah D, Libanati C, Chavassieux P (2022) Modeling-based bone formation after 2 months of romosozumab treatment: results from the FRAME clinical trial. J Bone Miner Res 37:36\u201340","journal-title":"J Bone Miner Res"},{"key":"1750_CR35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1210\/clinem\/dgad496","volume":"109","author":"SK Ramchand","year":"2024","unstructured":"Ramchand SK, Leder BZ (2024) Sequential therapy for the long-term treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 109:303\u2013311","journal-title":"J Clin Endocrinol Metab"},{"key":"1750_CR36","doi-asserted-by":"publisher","first-page":"3785","DOI":"10.1210\/jc.2008-0353","volume":"93","author":"PD Miller","year":"2008","unstructured":"Miller PD, Delmas PD, Lindsay R et al (2008) Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. J Clin Endocrinol Metab 93:3785\u20133793","journal-title":"J Clin Endocrinol Metab"},{"key":"1750_CR37","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1210\/jc.2007-0711","volume":"93","author":"S Boonen","year":"2008","unstructured":"Boonen S, Marin F, Obermayer-Pietsch B et al (2008) Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 93:852\u2013860","journal-title":"J Clin Endocrinol Metab"},{"key":"1750_CR38","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390:1585\u20131594","journal-title":"Lancet"},{"key":"1750_CR39","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1002\/jbmr.3452","volume":"33","author":"MR McClung","year":"2018","unstructured":"McClung MR, Brown JP, Diez-Perez A et al (2018) Effects of 24 months of treatment with romosozumab followed by 12 months of denosumab or placebo in postmenopausal women with low bone mineral density: a randomized, double-blind, phase 2, parallel group study. J Bone Miner Res 33:1397\u20131406","journal-title":"J Bone Miner Res"},{"key":"1750_CR40","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.bone.2017.11.003","volume":"107","author":"G Holdsworth","year":"2018","unstructured":"Holdsworth G, Greenslade K, Jose J, Stencel Z, Kirby H, Moore A, Ke HZ, Robinson MK (2018) Dampening of the bone formation response following repeat dosing with sclerostin antibody in mice is associated with up-regulation of Wnt antagonists. Bone 107:93\u2013103","journal-title":"Bone"},{"key":"1750_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.maturitas.2024.108066","volume":"188","author":"A Lawton","year":"2024","unstructured":"Lawton A, Tripodi N, Feehan J (2024) Running on empty: exploring stem cell exhaustion in geriatric musculoskeletal disease. Maturitas 188:108066","journal-title":"Maturitas"},{"key":"1750_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S2213-8587(25)00323-7","volume":"14","author":"S Khosla","year":"2026","unstructured":"Khosla S (2026) 3 months of romosozumab: a pragmatic clinical solution. Lancet Diabetes Endocrinol 14:189\u2013190","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1750_CR43","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1111\/cas.16066","volume":"115","author":"M Sakurai","year":"2024","unstructured":"Sakurai M, Ishitsuka K, Becker HJ, Yamazaki S (2024) Ex vivo expansion of human hematopoietic stem cells and clinical applications. Cancer Sci 115:698\u2013705","journal-title":"Cancer Sci"},{"key":"1750_CR44","doi-asserted-by":"publisher","first-page":"1625969","DOI":"10.3389\/fendo.2025.1625969","volume":"16","author":"Y Zhang","year":"2025","unstructured":"Zhang Y, Liu Y, Wang S, Wang C (2025) Therapeutic effects of mesenchymal stem cell-derived extracellular vesicles in osteoporosis models: a systematic review and meta-analysis of preclinical studies. Front Endocrinol (Lausanne) 16:1625969","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1750_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1002\/jbmr.4433","volume":"37","author":"R Eastell","year":"2022","unstructured":"Eastell R, Vittinghoff E, Lui LY et al (2022) Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH-ASBMR SABRE Project. J Bone Miner Res 37:29\u201335","journal-title":"J Bone Miner Res"},{"key":"1750_CR46","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S2213-8587(24)00092-5","volume":"12","author":"DM Black","year":"2024","unstructured":"Black DM, Thompson AR, Eastell R, Bouxsein ML (2024) Bone mineral density as a surrogate endpoint for fracture risk reduction in clinical trials of osteoporosis therapies: an update on SABRE. Lancet Diab Endocrinol 12:371\u2013373","journal-title":"Lancet Diab Endocrinol"}],"container-title":["Archives of Osteoporosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01750-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11657-026-01750-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11657-026-01750-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T10:10:49Z","timestamp":1786702249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11657-026-01750-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1750"],"URL":"https:\/\/doi.org\/10.1007\/s11657-026-01750-5","relation":{},"ISSN":["1862-3514"],"issn-type":[{"value":"1862-3514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]},"assertion":[{"value":"19 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"118"}}